Toxicokinetics: Overview

Toxicokinetics and pharmacokinetics both study drug absorption, distribution, metabolism, and excretion (ADME), but they focus on different dose ranges. Toxicokinetics examines high, toxic doses that may cause nonlinear kinetics due to saturated processes like enzymatic metabolism and protein binding, whereas pharmacokinetics studies therapeutic doses that typically exhibit linear kinetics.

At toxic doses, drugs may exceed their solubility limits in the intestines, leading to precipitation. This altered solubility affects absorption and bioavailability compared to therapeutic doses. Additionally, saturated metabolic and binding processes at high doses create nonlinear kinetics, complicating toxicokinetic predictions.

Toxicodynamics (TD) explores the relationship between toxic drug doses and resulting adverse effects. Combined with toxicokinetics, TD studies correlate animal toxicity data with human safety by estimating human equivalent doses and maximum recommended starting doses, validating animal models and identifying target organs for toxicity.

Preclinical toxicokinetic studies translate animal toxicity data to human contexts, enabling FDA approval and global drug regulation. They validate animal models, determine safe starting doses for human trials, design dose regimens, and provide insights for clinicians to establish safety margins and for pathologists to understand drug toxicity mechanisms.

At toxic doses, enzymatic metabolism and protein binding become saturated, shifting from linear to nonlinear kinetics. This saturation means that small increases in dose can produce disproportionately large increases in drug concentration and toxicity, unlike the predictable linear relationship observed at therapeutic doses.

Toxicokinetic data help reproductive and developmental toxicologists select appropriate doses in teratology studies by clarifying how drugs are absorbed, distributed, metabolized, and excreted at toxic levels. This information ensures safe dose selection and helps predict adverse developmental effects in preclinical research.

Understanding toxicokinetics helps predict adverse drug reactions (ADRs) by clarifying how drugs behave at high doses where nonlinear kinetics and altered physiological processes occur. This knowledge enables clinicians and researchers to establish appropriate safety margins and manage toxicity in humans throughout drug development and post-marketing surveillance.